Skip to main content
Top
Published in: Respiratory Research 1/2022

Open Access 01-12-2022 | Pneumonia | Correspondence

Prevalence of type-1 interferon autoantibodies in adults with non-COVID-19 acute respiratory failure

Authors: Rajani Ghale, Natasha Spottiswoode, Mark S. Anderson, Anthea Mitchell, Grace Wang, Carolyn S. Calfee, Joseph L. DeRisi, Charles R. Langelier

Published in: Respiratory Research | Issue 1/2022

Login to get access

Abstract

Auto-antibodies (Abs) to type I interferons (IFNs) are found in up to 25% of patients with severe COVID-19, and are implicated in disease pathogenesis. It has remained unknown, however, whether type I IFN auto-Abs are unique to COVID-19, or are also found in other types of severe respiratory illnesses. To address this, we studied a prospective cohort of 284 adults with acute respiratory failure due to causes other than COVID-19. We measured type I IFN auto-Abs by radio ligand binding assay and screened for respiratory viruses using clinical PCR and metagenomic sequencing. Three patients (1.1%) tested positive for type I IFN auto-Abs, and each had a different underlying clinical presentation. Of the 35 patients found to have viral infections, only one patient tested positive for type I IFN auto-Abs. Together, our data suggest that type I IFN auto-Abs are uncommon in critically ill patients with acute respiratory failure due to causes other than COVID-19.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585.CrossRef Bastard P, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585.CrossRef
2.
go back to reference van der Wijst MGP, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021;13:eabh2624.CrossRef van der Wijst MGP, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021;13:eabh2624.CrossRef
3.
go back to reference Bastard P, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6:eabl4340.CrossRef Bastard P, et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol. 2021;6:eabl4340.CrossRef
4.
go back to reference Goncalves D. et al. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients. Clin Transl Immunol. 2021;10. Goncalves D. et al. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients. Clin Transl Immunol. 2021;10.
5.
go back to reference Bastard P, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021;218: e20210554.CrossRef Bastard P, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021;218: e20210554.CrossRef
7.
go back to reference Meager A, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003;132:128–36.CrossRef Meager A, et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 2003;132:128–36.CrossRef
8.
go back to reference Wu W, Metcalf JP. The role of type I IFNs in influenza: antiviral superheroes or immunopathogenic villains? J Innate Immun. 2020;12:437–47.CrossRef Wu W, Metcalf JP. The role of type I IFNs in influenza: antiviral superheroes or immunopathogenic villains? J Innate Immun. 2020;12:437–47.CrossRef
9.
go back to reference Sarma A, et al. Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS. Nat Commun. 2021;12:5152.CrossRef Sarma A, et al. Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS. Nat Commun. 2021;12:5152.CrossRef
Metadata
Title
Prevalence of type-1 interferon autoantibodies in adults with non-COVID-19 acute respiratory failure
Authors
Rajani Ghale
Natasha Spottiswoode
Mark S. Anderson
Anthea Mitchell
Grace Wang
Carolyn S. Calfee
Joseph L. DeRisi
Charles R. Langelier
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2022
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-022-02283-4

Other articles of this Issue 1/2022

Respiratory Research 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.